-- Results date: 27 February 2013 --

Oxford, UK - 23 January 2013: Oxford BioMedica plc (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its preliminary results for the twelve months ended 31 December 2012 on Wednesday, 27 February 2013.

An analyst briefing will be held at 09:30am GMT on Wednesday, 27 February 2013 at the offices of M:Communications, 11th Floor, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW. An audio replay will be made available shortly after the presentation on the Company's website: www.oxfordbiomedica.co.uk.

- Ends -

Notes to editors

1.

Oxford BioMedica plc
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp.www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

For further information please contact:
Oxford BioMedica plc
Lara Mott, Head of Corporate Communications 		Tel: +44 (0)1865 783 000
N+1 Singer
Shaun Dobson/Graeme Summers/Jenny Wyllie 		Tel: +44 (0)20 3205 7500
M: Communications Media/Financial Enquiries
Mary Clark/Sarah Macleod/Claire Dickinson 		Tel: +44 (0)20 7920 2360
distributed by